Extended Data Fig. 4: Peptide-encoding small circRNA vaccine elicit stronger and more durable T-cell responses than protein-encoding unmodified mRNA and large circRNA vaccines in young adult mice.
From: Small circular RNAs as vaccines for cancer immunotherapy
a, Design of T cell response study in mice. C57BL/6 mice (n = 4-5; 6-8 weeks) were immunized with circRNA-SIINFEKL, unmodified mRNA-OVA, and large circRNA code OVA protein at 3 μg and 10 μg doses, respectively. b, 120-day kinetics of the PBMC SIINFEKL-specific CD8+ T cell percentages in the above immunized mice, suggesting that circRNA-SIINFEKL elicited overall stronger and more durable T cell responses than OVA-encoding unmodified mRNA and large circRNA vaccines. Asterisks: statistical significance of the T cell fraction AUC relative to that for circRNA. c, circRNA-SIINFEKL elicited larger fractions of memory T cells (Tem + Tcm) than unmodified mRNAs (day 90), indicating great T cell memory elicited by small circRNA vaccine. Data were quantified from CD44 and CD62L staining of PBMC CD8+ T cells.
